DFP-14927 is under clinical development by Delta-Fly Pharma and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DFP-14927’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DFP-14927 overview
DFP-14927 is under development for the treatment of solid tumors including gastroesophageal cancer, pancreatic cancer, cholangiocarcinoma, refractory acute myeloid leukemia, relapsed acute myeloid leukemia, colorectal cancer and myeloblastic syndrome. It is administered by intravenous route. The drug candidate is a polymeric derivative that gets activated in the vicinity of the tumor by the action of enzymes such as MMP and releases the anticancer active substance.
Delta-Fly Pharma overview
Delta-Fly Pharma is a biopharmaceutical and healthcare company. The company discovers and develops anti-cancer agents. Its product portfolio includes DFP-10917, used in the treatment of myelogenous leukemia; DFP-14323, an anticancer drug candidate treating lung cancer; and DFP-10825, a liposome-conjugated RNAi molecule that targets disseminated ovarian and gastric cancer. Delta-Fly Pharma also develops DFP-11207, a cancer cell metabolism regulator that treats stomach cancer; and DFP-14927, a Polymeric anti-cancer agent, used in the treatment of solid tumors. The company develops novel products using module technology (Module Drug Discovery). It has its operations across Japan, Canada, and China. Delta-Fly Pharma is headquartered in Tokushima-Shi, Tokushima, Japan.
For a complete picture of DFP-14927’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
